Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Satial is a dietary supplement developed by Framingham Pharma and marketed by Laboratorios Vanquish, primarily indicated for weight management and the reduction of carbohydrate absorption. Its active ingredient is a standardized extract of *Phaseolus vulgaris* (white kidney bean), which functions as a natural inhibitor of the enzyme alpha-amylase. By interfering with the enzymatic breakdown of starches into glucose, Satial reduces the glycemic index of meals and limits the caloric intake derived from complex carbohydrates. It is commonly available in powder or tablet form and is marketed as a "carb blocker" to be used in conjunction with starchy meals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Satial.